PE20060826A1 - Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende - Google Patents
Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprendeInfo
- Publication number
- PE20060826A1 PE20060826A1 PE2005001396A PE2005001396A PE20060826A1 PE 20060826 A1 PE20060826 A1 PE 20060826A1 PE 2005001396 A PE2005001396 A PE 2005001396A PE 2005001396 A PE2005001396 A PE 2005001396A PE 20060826 A1 PE20060826 A1 PE 20060826A1
- Authority
- PE
- Peru
- Prior art keywords
- octane
- pharmaceutical combination
- dry powder
- preferred
- powder inhaler
- Prior art date
Links
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 title abstract 2
- 229940112141 dry powder inhaler Drugs 0.000 abstract 2
- -1 2,2-DI-2-THENYLETHENYL Chemical class 0.000 abstract 1
- 229940124225 Adrenoreceptor agonist Drugs 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003470 adrenal cortex hormone Substances 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229960000289 fluticasone propionate Drugs 0.000 abstract 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 229960005018 salmeterol xinafoate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE ACETILCOLINA MUSCARINICO TAL COMO: BROMURO DE (3-ENDO)-3-(2,2-DI-2-TIENILETENIL)-8,8-DIMETIL-8-AZONIABICICLO[3.2.1]OCTANO Y UNO O MAS INGREDIENTES ACTIVOS TAL COMO i) UN AGONISTA ADRENORRECEPTOR ß-2 SIENDO PREFERIDO XINAFOATO DE SALMETEROL; Y ii) UN AGENTE CORTICOSTEROIDE ANTIINFALAMATORIO SIENDO PREFERIDO PROPIONATO DE FLUTICASONA. ESTA COMBINACION ES UTIL PARA EL TRATAMIENTO EN LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, BRONQUITIS CRONICA, ASMA, OBSTRUCCION RESPIRATORIA CRONICA, FIBROSIS PULMONAR, EFISEMA PULMONAR Y RINITIS ALERGICA. LA ADMINISTRACION SE REALIZA MEDIANTE UN DISPENSADOR SELECCIONADO DE UN INHALADOR DE POLVO SECO EN UN DEPOSITO, UN INHALADOR DE POLVO SECO EN MULTIPLES DOSIS O EN DOSIS MEDIDAS, CON UNA DURACION DE ACCION DE 12 HORAS A MAS, PARA UNA DOSIS DE 1 MG
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63361804P | 2004-12-06 | 2004-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060826A1 true PE20060826A1 (es) | 2006-10-08 |
Family
ID=36578468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001396A PE20060826A1 (es) | 2004-12-06 | 2005-12-01 | Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR052145A1 (es) |
| PE (1) | PE20060826A1 (es) |
| TW (1) | TW200633715A (es) |
| UY (1) | UY29245A1 (es) |
| WO (1) | WO2006062931A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050250A1 (es) | 2003-07-17 | 2005-04-08 | Glaxo Group Ltd | Antagonistas de los receptores muscarinicos de la acetilcolina |
| TW200811172A (en) | 2003-10-14 | 2008-03-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| AR046114A1 (es) | 2003-10-17 | 2005-11-23 | Glaxo Group Ltd | Compuesto de 8- azoniabiciclo (3.2.1) octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion |
| TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| US7384946B2 (en) | 2004-03-17 | 2008-06-10 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| PE20060259A1 (es) | 2004-04-27 | 2006-03-25 | Glaxo Group Ltd | Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico |
| JP2007537261A (ja) | 2004-05-13 | 2007-12-20 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
| US7932247B2 (en) | 2004-11-15 | 2011-04-26 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| EP1937068A4 (en) | 2005-08-18 | 2010-08-04 | Glaxo Group Ltd | ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| UY31637A1 (es) | 2008-02-06 | 2009-08-03 | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
| UY31636A1 (es) | 2008-02-06 | 2009-08-03 | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
| AR070564A1 (es) | 2008-02-06 | 2010-04-21 | Glaxo Group Ltd | Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden |
| PT3578169T (pt) | 2009-02-26 | 2024-07-29 | Glaxo Group Ltd | Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| US20140113888A1 (en) * | 2011-06-08 | 2014-04-24 | Glaxo Group Limited | Novel Combination of Therapeutic Agents |
| CN104470503A (zh) | 2012-04-13 | 2015-03-25 | 葛兰素史克知识产权开发有限公司 | 聚集粒子 |
| GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1140998B (it) * | 1980-06-18 | 1986-10-10 | Valeas Ind Chimica E Farmaceut | Sali di endo-8-metil-8-sin-alchil-8-azoniabiciclo aperta par. quadrata 3.2.1. chiusa par. quadrata-ottan-3-alchilcarbossilati, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo |
| IT1194343B (it) * | 1983-07-26 | 1988-09-14 | Valeas Spa | Sali di endo-8,8-dialchil-8-azoniabiciclo (3.2.1) ottan-6,7-esso-epossi-3-alchilcarbossilati,processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo |
| DE19528145A1 (de) * | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
| US20030013675A1 (en) * | 2001-05-25 | 2003-01-16 | Boehringer Ingelheim Pharma Kg | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases |
-
2005
- 2005-12-01 PE PE2005001396A patent/PE20060826A1/es not_active Application Discontinuation
- 2005-12-02 UY UY29245A patent/UY29245A1/es unknown
- 2005-12-05 AR ARP050105079A patent/AR052145A1/es unknown
- 2005-12-05 WO PCT/US2005/044033 patent/WO2006062931A2/en not_active Ceased
- 2005-12-05 TW TW094142714A patent/TW200633715A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR052145A1 (es) | 2007-03-07 |
| TW200633715A (en) | 2006-10-01 |
| UY29245A1 (es) | 2006-05-31 |
| WO2006062931A2 (en) | 2006-06-15 |
| WO2006062931A3 (en) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060826A1 (es) | Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende | |
| Cazzola et al. | Long-acting muscarinic receptor antagonists for the treatment of respiratory disease | |
| ES2468840T7 (es) | Terapia combinada para EPOC | |
| ES2828070T3 (es) | Métodos para tratar trastornos autoinmunitarios, respiratorios e inflamatorios mediante la inhalación de n-oxido de roflumilast | |
| PE20091672A1 (es) | Nueva dosificacion y formulacion | |
| US20070202055A1 (en) | Pharmaceutical Formulations | |
| JP2006501253A (ja) | 新規抗コリン作用剤をコルチコステロイド及びβ模倣薬と共に含有する吸入用医薬組成物 | |
| AU2012216890A1 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
| US20090238771A1 (en) | Pharmaceutical formulations | |
| ES2961242T3 (es) | Terapia combinada para la EPOC | |
| JP2005502608A (ja) | 抗コリン作用剤とコルチコステロイドとβ刺激剤を含む新規な医薬組成物 | |
| JP2009526062A (ja) | 薬学的処方物 | |
| EP1819329A2 (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases | |
| JOP20200314A1 (ar) | تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| ES2467928T3 (es) | Formulación en aerosol para EPOC | |
| KR20180118667A (ko) | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 | |
| IL155676A (en) | Liquid, propellant-free pharmaceutical preparation containing a tiotropium salt and another active substance and its use in the manufacture of a medicament for treating asthma or copd | |
| Sethi et al. | Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease | |
| Glossop et al. | Progress in the development of inhaled, long-acting β2-adrenoceptor agonists | |
| JP2008509196A (ja) | コルチコステロイド、β模倣薬及び新規な抗コリン作用薬を含有する吸入用薬剤 | |
| JP2008538758A (ja) | 抗コリン作用薬に加えてベータ受容体刺激薬及びステロイドを含有する吸入用の医薬組成物 | |
| JP2006517216A (ja) | 抗コリン作用剤とｔａｃｅ阻害剤に基づく新規な医薬組成物 | |
| JP2006517213A (ja) | 新規な抗コリン作用剤とＴＮＦα合成又は作用阻害剤に基づく新規な医薬組成物 | |
| JP2008530177A (ja) | 抗コリン作用薬及びエチプレドノールを含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |